glutathione meniere's disease and neurodegenerative diseases: immunopharmacological implications Sound Pharmaceuticals concludes subject enrolment
Sound Pharmaceuticals concludes subject enrolment for SPI 1005 trial SPI 1005 for Meniere's Disease Info for Participants Phase Phase 3 Clinical Trial 2026 Power Power Nineteen year follow up of a patient with severe glutathione synthetase deficiency Journal of Human Genetics Sound Pharmaceuticals Meniere's Disease Treatment Phase 3 Study Complete The Hearing Review Meniere disease and ebselen: anti neoplastic may help manage symptoms
Pay in 4 interest-free payments of $6.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5




